MDT: Bull Flag detected on 14 Jul 2026

MDT moved above its 50-day moving average on July 01, 2026, indicating a transition from downward trend to upward trend. A bull flag pattern is forming with the stock at $83.57, trapped between key support at $81.10 and resistance at $85.99. Structure score of 13.4 and volume score of 12.0 indicate good pattern definition, though volume during the consolidation phase remains subdued at 53% of the 20-day average (4.9M vs. 9.2M). Breakout score of 11.2 reflects moderate momentum; the RSI at 59.72 shows neutral positioning with no overbought extremes, while MACD histogram is positive at 0.307. The overall score of 78.6 and 72.58% win probability suggest reasonable setup quality for an upside breakout toward $86.33.

On July 10, 2026, Medtronic shares climbed on optimism regarding enhanced reimbursement for its renal denervation therapy, with an analyst from Leerink Partners highlighting that this move could significantly promote adoption of the therapy, pending a favorable review in September 2026. In recent weeks, Medtronic reported fourth-quarter fiscal 2026 results with revenue growth, an adjusted earnings per share beat, a higher dividend, and new fiscal 2027 guidance, while also expanding its commercial partnership with Retia Medical to distribute the Argos Cardiac Output Monitor. Medtronic is acquiring SPR Therapeutics for $650 million to enhance its pain management portfolio, and despite recent stock price declines, analysts indicate shares are undervalued, trading approximately 27% below target prices. The stock trades 19.5% below its 52-week high of $104.04 but has gained 5.1% over the past month as bullish catalysts accumulate in cardiovascular and renal therapy segments.

A bull flag breakout above $85.99 resistance would target the conservative measured move of $86.33, representing 3.3% upside from current levels. Historical data suggests that in 40 similar past instances where MDT moved above its 50-day moving average, the stock price increased further within the following month. Volume confirmation is critical—breakout should exceed the 9.2M 20-day average to validate the move. The pattern invalidates on close below key support at $81.10, representing 3.0% downside risk. The 72.58% win probability indicates better-than-even odds, though the setup requires disciplined entry near resistance and strict adherence to the support level.

Over the past three months, insiders sold $0.6 million worth of shares, indicating some caution among company executives. The September 2026 reimbursement decision for renal denervation therapy is binary—unfavorable CPT code approval could trigger reversal of recent gains. Volume remains anemic at 53% of normal; if the breakout fails to generate above-average participation, the move will lack conviction. Healthcare sector is bullish (0.83 score) but broader market regime is only moderately bullish (0.54), creating potential headwinds. Since the start of this year, Medtronic's stock has sunk 16% and traded near the bottom of its 52-week range in late May, reflecting persistent investor skepticism despite fundamental improvements. The low beta of 0.52 offers downside protection but may limit upside momentum if broader healthcare rallies unexpectedly.

We scan more than 6,000 NYSE and NASDAQ stocks every trading day and compare each detected pattern against a database of 370,000+ historical detections. Every setup is scored across three dimensions: Structure, Volume, and Breakout Readiness. Win probability is a calibrated estimate of how similar historical setups performed over the following 10 trading days. This is a swing trading tool built for multi-day holds. It is not built or tested for day trading.